This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA. If you would like continuing education credit for the webinar, click on the links in the table below to access the webinar + CME/CMLE or webinar + SAM


Lauren Ritterhouse MD, PhD


Susan Hsiao MD, PhD


Description:  This webinar will cover the background and rationale for the use of tumor mutational burden (TMB) as a biomarker for immunotherapy in oncology. The various biomarkers that have been evaluated for immunotherapy will be explored and a discussion of TMB’s role and use in oncology will be made. The course will cover an overview of immunotherapy drugs, targets, and tumor types for which TMB has been used as a biomarker.

Duration: 1 hr

Level of Instruction: Basic


This webinar is part 1 of a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here

This program has been supported through an educational grant from Bristol-Myers Squibb.

Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:

Purchase Webinar + CME/CMLE

(Free for all)

SAM 1.0

Purchase Webinar + SAM

(Free for all)

Continuing Education Credit must be purchased and claimed by December 31, 2020


* You may not submit SAMs and CME/CMLE credit for the same content.

You may also be interested in:


Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.




Course Information
Course Date:
June 27, 2018
Course Objectives
  • Describe the clinical utilization of TMB in oncology.
  • Define TMB and the rationale for its use as a biomarker for immunotherapy in oncology.
Pre-Test for TMB: Clinical and Diagnostic Utilization in Oncology (CE Available)
Tumor Mutational Burden: Clinical and Diagnostic Utilization in Oncology
Post-Test for TMB: Clinical and Diagnostic Utilization in Oncology (CE Available)
QA Session
Individual topic purchase: Selected
Ritterhouse Presentation
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00